Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reiterated a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday, April 4th.

Galmed Pharmaceuticals Stock Up 1.4 %

GLMD opened at $1.40 on Monday. Galmed Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $23.80. The stock has a market cap of $2.32 million, a PE ratio of -0.08 and a beta of 0.70. The business has a 50 day moving average of $1.88 and a 200-day moving average of $2.69.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 76.14% of the stock is currently owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.